News News Review
CDF shake-up / GPs and pharma’s growing divide / Dead end for off-patent drugs bill / Pharma’s transparency drive
SmartViews Education, education, education
Pharma has a crucial role in providing medical education, but must be fully transparent
Rise of the machines
Artificial intelligence is the key to smarter procurement and cost savings
Medical devices under the microscope
Medical devices could soon come under increased scrutiny as the EU’s new regulation proposals enter final discussions
Pharma companies in a dominant market position need to be sure they are not abusing their position or risk the consequences
Battle of the Pacific
What the Trans-Pacific trade deal means for pharma
Recent trends in pharma M&A / Pfizer in talks to acquire Allergan / AstraZeneca snaps up ZS Pharma / Shire buys potential competitor Dyax
Features Taking a breath
Pharma’s role in tackling the challenges of Chronic Obstructive Pulmonary Disease
Voyage of rediscovery
Repurposing drugs can be a quick, inexpensive solution to diseases, but pharma has to be careful when repricing older medicines
Uniphar’s Padraic Dempsey on the healthcare industry in the UK and Ireland
This month’s job moves and new appointments
COPD patient Joan McCarthy says that pharma could do more to educate COPD patients
Business Insight Zenopa
It only takes one applicant to fill a job
Click here to see the latest PharmaTimes Magazine
To subscribe go to www.pharmatimes.com/subscribe; digital available from:
Outcomes: a gamechanger for pharma
Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?
Healthcare Writer Lynne Taylor
The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.
Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.
Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.
So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here
See what's coming up in the March issue [PDF]
Visions 2014 supplement
Creating a balance between
reimbursement and innovation
How to plan early
What more does pharma need to do?
We asked you what the big developments in 2014 will be?
Change is key to opportunity
What to adapt for
Future-proofing the sales team
An example of a new R&D model
Visions in a nutshell
The complete Visions 2014 supplement PDF is available to download
Subscription is free to qualifying UK subscribers
To read articles in full and features in the magazine, why not subscribe
PharmaTimes Magazine print and digital versions have a total circulation of 23,184, including 8,000 NHS healthcare professionals: chief pharmacists, medicines management and primary care commissioners.
Follow us: @PharmaTimes on Twitter